Identification of 1-{2-[4-chloro-1′-(2,2-dimethylpropyl)-7-hydroxy-1, 2-dihydrospiro[indole-3,4′-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3] thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y1 antagonist as an antiplatelet agent

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 5, 2014, Pages 1294-1298

  Jeon, Yoon T ^a   Yang, Wu ^a   Qiao, Jennifer X ^a   Li, Ling ^a   Ruel, Rejean ^a   Thibeault, Carl ^a   Hiebert, Sheldon ^a   Wang, Tammy C ^a   Wang, Yufeng ^a   Liu, Yajun ^a   Clark, Charles G ^a   Wong, Henry S ^a   Zhu, Juliang ^a   Wu, Dauh Rurng ^a   Sun, Dawn ^a   Chen, Bang Chi ^a   Mathur, Arvind ^a   Chacko, Silvi A ^a   Malley, Mary ^a   Chen, Xue Qing ^a   Shen, Hong ^a   Huang, Christine S ^a   Schumacher, William A ^a   Bostwick, Jeffrey S ^a   Stewart, Anne B ^a   Price, Laura A ^a   Hua, Ji ^a   Li, Danshi ^a   Levesque, Paul C ^a   Seiffert, Dietmar A ^a   Rehfuss, Robert ^a   Wexler, Ruth R ^a   Lam, Patrick Y S ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiplatelet agent; P2Y1 antagonist; Spiropiperidinylindolines

Indexed keywords

ANTIPLATELET AGENT; P2Y(1) ANTAGONIST; SPIROPIPERIDINYLINDOLINES;

ADMINISTRATION, ORAL; ANIMALS; DOGS; HALF-LIFE; MACACA FASCICULARIS; PHENYLUREA COMPOUNDS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2Y1; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THROMBOSIS; UREA;

EID: 84894600266     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.01.066     Document Type: Article

References (25)

1. B. Hechler, and C. Gachet Purinergic Signalling 7 2011 293
2. K.A. Jacobson, F. Deflorian, S. Mishra, and S. Costanzi Purinergic Signalling 7 2011 305
3. C. Gachet Thromb. Haemost. 99 2008 466
4. M. Cattaneo Expert Rev. Cardiovasc. Ther. 5 2007 45
5. C. Gachet, C. Léon, and B. Hechler Blood Cells Mol. Dis. 36 2006 223
6. C. Oury, E. Toth-Zsamboki, J. Vermylen, and M.F. Hoylaerts Curr. Pharm. Des. 12 2006 859 and references cited therein
7. C. Gachet Annu. Rev. Pharmacol. Toxicol. 46 2006 277
8. M. Cattaneo Drug News Perspect. 19 2006 253
9. S. Murugappan, and S.P. Kunapuli Front. Biosci. 2006 1977 11
10. B. Hechler, M. Cattaneo, and C. Gachet Semin. Thromb. Hemost. 312 2005 150
11. J.-M. Herbert Expert Opin. Investig. Drugs 13 2004 457
12. B. Hechler, C. Nonne, E.J. Roh, M. Cattaneo, J.P. Cazenave, F. Lanza, K.A. Jacobson, and C. Gachet J. Pharmacol. Exp. Ther. 316 2006 556
13. H. Chao, H. Turdi, T.F. Herpin, J.Y. Roberge, Y. Liu, D.M. Schnur, M.A. Poss, R. Rehfuss, J. Hua, Q. Wu, L.A. Price, L.M. Abell, W.A. Schumacher, J.S. Bostwick, T.E. Steinbacher, M.L. Ogletree, C.S. Huang, M. Chang, A.M. Cacace, M.J. Arcuri, D. Celani, R.R. Wexler, and R.M. Lawrence J. Med. Chem. 56 2013 1704
14. T.C. Wang, J.X. Qiao, C.G. Clark, J. Hua, L.A. Price, Q. Wu, M. Chang, J. Zheng, C.S. Huang, G. Everlof, W.A. Schumacher, P.C. Wong, D.A. Seiffert, A.B. Stewart, J.S. Bostwick, E.J. Crain, C.A. Watson, R. Rehfuss, R.R. Wexler, and P.Y.S. Lam Bioorg. Med. Chem. Lett. 23 2013 3239
15. J.X. Qiao, T.C. Wang, R. Ruel, C. Thibeault, A. L'Heureux, W.A. Schumacher, S.A. Spronk, S. Hiebert, G. Bouthillier, J. Lloyd, Z. Pi, D. Schnur, L.M. Abell, L.A. Price, F. Liu, Q. Wu, T.E. Steinbacher, J.S. Bostwick, M. Chang, J. Zheng, Q. Gao, B. Ma, P.A. McDonnell, C.S. Huang, R. Rehfuss, R.R. Wexler, and P.Y.S. Lam J. Med. Chem. 56 2013 9275
16. For recent publications on non-nucleotide small molecule P2Y1 antagonists, see: J.A. Pfefferkorn, C. Choi, T. Winters, R. Kennedy, L. Chi, L.A. Perrin, G. Lu, Y.-W. Ping, T. McClanahan, R. Schroeder, M.T. Leininger, A. Geyer, S. Schefzick, and J. Atherton Bioorg. Med. Chem. Lett. 18 2008 3338
17. A.I. Morales-Ramos, J.S. Mecom, T.J. Kiesow, T.L. Graybill, G.D. Brown, N.V. Aiyar, E.A. Davenport, L.A. Kallal, B.A. Knapp-Reed, P. Li, A.T. Londregan, D.M. Morrow, S. Senadhi, R.K. Thaljil, S. Zhao, C.L. Burns-Kurtis, and J.-P. Marino Bioorg. Med. Chem. Lett. 18 2008 6222
18. D. Houston, S. Costanzi, K.A. Jacobson, and T.K. Harden Comb. Chem. High Throughput Screening 11 2008 410
19. R.K. Thalji, N. Aiyar, E.A. Davenport, J.A. Erhardt, L.A. Kallal, D.M. Morrow, S. Senadhi, C.L. Burns-Kurtis, and J.P. Marino Jr. Bioorg. Med. Chem. Lett. 20 2010 4104
20. Z. Pi, J. Sutton, J. Lloyd, J. Hua, L. Price, Q. Wu, M. Chang, J. Zheng, R. Rehfuss, C.S. Huang, R.R. Wexler, and P.Y.S. Lam Bioorg. Med. Chem. Lett. 23 2013 4206
21. R. Ruel, A. L'Heureux, C. Thibeault, P. Lapointe, A. Martel, J.X. Qiao, J. Hua, L.A. Price, Q. Wu, M. Chang, J. Zheng, C.S. Huang, R.R. Wexler, R. Rehfuss, and P.Y.S. Lam Bioorg. Med. Chem. Lett. 23 2013 6825
22. J.X. Qiao, T.C. Wang, C. Hu, J. Li, R.R. Wexler, and P.Y.S. Lam Org. Lett. 13 2011 1804
23. A fluorescent agent, dansylglutathione(5-(dimethylamino)naphthalene-1- sulfonyl glutathione) (dGSH) was utilized to give a quantitative estimate of GSH adduct formed in human liver microsomes. For fluorescent compounds or for those which form fluorescent metabolites, underivatized glutathione (GSH) was utilized as an in vitro trapping agent, in which case the reactive metabolites were characterized and semiquantitated with HPLC-UV-MS (Finnigan LTQ) J. Gan, T.W. Harper, M. Hsueh, Q. Qu, and W.G. Humphreys Chem. Res. Toxicol. 18 2005 896
24. J. Gan, Q. Ruan, B. He, M. Zhu, W.C. Shyu, and W.G. Humphreys Chem. Res. Toxicol. 22 2009 690
25. W.A. Schumacher, J.S. Bostwick, M.L. Ogletree, A. Stewart, T.E. Steinbacher, J. Hua, L. Price, P.C. Wong, and R. Rehfuss J. Pharmacol. Exp. Ther. 322 2007 369